CHU Toulouse receives CTA Approval to initiate ALLOFIST, a Phase 1/2 Trial based on Cell-Easy’s proprietary adipose-derived MSC in Patients suffering from Crohn Disease. Toulouse, France, January 15, 2025 The long-term partnership between Cell-Easy and Toulouse University Hospital (CHU Toulouse) continues to bear fruits, bringing innovative MSC-based therapies to
Cell-Easy Expands US Footprint with Key Contract Signing for Master Cell Bank (MCB) and Working Cell Bank (WCB) Manufacturing Services. Toulouse, France, May 14, 2024 – Cell-Easy, a European Contract Development and Manufacturing Organization (CDMO) specializing in Cell Therapy, announces a significant milestone with the signing of a Cell
Accelerating Patient Access to Advanced Cell-based Therapies through the Signature of a Service Agreement between the French CDMO and the Toulouse University Hospital (CHU Toulouse) Toulouse, France, April 18, 2024 – This agreement between the two parties opens great perspectives for Biotechs, providing them with seamless access to patients who
Cell-Easy Signs Groundbreaking Manufacturing Contract, Paving the Way for Local Hospitals to Offer Next-Generation CAR-T Therapy Toulouse, France, march 26, 2024 – This agreement with a pioneer European C&G company will soon enable the initiation of new clinical trials in South of France based on innovative CAR-T cell treatments
EU regulatory approval to administer Adipose-derived mesenchymal Stem Cells (ASCs) in patients with ischemic digital ulcers marks key milestone for partners Toulouse, France, November 16, 2023 – Cell-Easy, a French Contract Development and Manufacturing Organization (CDMO) focused on advanced cell therapies, and the Toulouse University Hospital, today announce that they
Toulouse, France, September 21st of 2023 Cell-Easy, a specialized contract development and manufacturing organization (CDMO) in cell therapy, proudly announces the appointment of Mrs. Gisele Deblandre as the Chief Scientific Officer. Over the years, Cell-Easy has recognized the challenges faced by biotechs in bridging the gap between early-stage projects
TOULOUSE, FRANCE, June 22, 2023 IUCT-Oncopole and Cell-Easy SAS (Cell-Easy) announced today the signing of a Memorandum of Understanding to enhance their strategic collaborative relationship and open access to advanced cell-based therapies. This partnership aims to drive innovation in public health and improve access to promising new cancer therapies for patients. By
